TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin), a type 2 diabetes (T2D) treatment, to patients in sub-Saharan Africa.

The collaboration is based on a shared mission between the two companies.

This initiative follows TheracosBio’s collaboration with SmithRx in August 2023 aimed at improving access to BRENZAVVY for adults with T2D.

TheracosBio CEO Brian Connelly stated: “The mission of TheracosBio is to bring effective treatments to patients in need at affordable prices and BAMCO is working to do the same for patients in sub-Saharan Africa.

“We are excited to work with BAMCO to provide doctors and their patients in the region with access to BRENZAVVY, a cost-effective therapy to manage type 2 diabetes.”

BRENZAVVY, an oral sodium-glucose cotransporter 2 inhibitor, received approval from the US Food and Drug Administration (FDA) in January 2023 and is now set to make its mark in the African market.

It is indicated for adults with T2D and an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2 or higher, which includes those with stage three chronic kidney disease.

BAMCO Africa CEO Markus Gemuend stated: “BAMCO’s mission is that all patients in sub-Saharan Africa deserve better and need to have equitable and timely access to the latest innovative treatments that save and improve their lives.

“We are thrilled to partner with TheracosBio to provide access to BRENZAVVY for patients with type 2 diabetes, a fast-growing health burden, and engage with medical communities to launch this innovative treatment in sub-Saharan Africa.”

Results from Phase III clinical trials have demonstrated that BRENZAVVY lowers haemoglobin A1c and fasting blood sugar levels over 24 weeks.

While not specifically approved for weight loss or reduction in blood pressure, clinical studies have noted positive improvements in these areas among patients taking the treatment.